Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

April 1, 2007
Oncology NEWS International, Oncology NEWS International Vol 16 No 4, Volume 16, Issue 4

Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

TOKYO, Japan—Eisai Co. Ltd and Eisai Corporation of North American (Woodcliff Lake, New Jersey) have signed a definitive agreement to acquire Morphotek (Exton, Pennsylvania) for $325 million. The acquisition is pending subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Morphotek develops therapeutic monoclonal antibodies and is evaluating two in early-stage clinical trials. Eisai's portfolio of oncology drugs currently includes small-molecule anticancer agents.